Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CMED, PROT, NPD, CPHI - Stock Alerts! from - China Medical Technologies, Proteonomix, China Nepstar Chain Drugstore, China Pharma Holdings

|Includes:China Pharma Holdings, Inc. (CPHI)







  Proteonomix, Inc. (OTCPK:PROT)

PROT, a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with its Joint Venture Company, XGEN Medical LLC towards implementing operations in the United Arab Emirates.

PROT CEO, Michael Cohen commented that "The business environment in the U.A.E. is very receptive to Proteonomix and our medical technologies. There is an intense focus on high quality public medical care as well as cutting edge technology. When combined with the rebounding financial condition within the region, we are very pleased to have this opportunity to conduct business in a growing location for medical advancement."

PROT, a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products. The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. It offers product for the treatment of anti-aging and damaged skin. PROT develops cosmetic products using its technologies, Secreted Matrix and Matrix NC-138 that is a stem cell derived proteins technology. PROT is also involved in the operation of retail Web site, to sell its anti-aging line of skin care products; develops therapeutic modalities for the treatment of cardiovascular disease; and engages in the reproductive tissue banking, including sperm, ova, ovarian tissue, and testicular tissue. In addition, PROT develops intellectual properties for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a cord blood banking cryopreservation bag, and a device to eliminate malformed stem cells via filtration. Further, PROT is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. PROT was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. PROT was founded in 2005 and is based in Mountainside, New Jersey.

To learn more about PROT visit:


China Medical Technologies, Inc. (Nasdaq:CMED)

CMED, a leading China-based advanced in-vitro diagnostic company, recently announced the filing of its annual report on Form 20-F for the fiscal year ended March 31, 2010 with the U.S. Securities and Exchange Commission. The annual report, which contains its audited consolidated financial statements for the fiscal year ended March 31, 2010, can be accessed on CMED's website

CMED, a medical device company, develops, manufactures, and markets advanced immunodiagnostic and molecular diagnostic products primarily in the People's Republic of China. CMED sells its products through distributors. CMED was founded in 1999 and is based in Beijing, the People's Republic of China.

To learn more about CMED visit:


China Nepstar Chain Drugstore Ltd. (NYSE:NPD)

NPD, the largest drugstore chain in China based on the number of directly operated stores, recently announced that its board of directors has authorized a share repurchase program. Under the terms of the approved program, NPD may repurchase up to US$20 million worth of its issued and outstanding American Depositary Shares from time to time over the next 12 months. The repurchases will be made on the open market at prevailing market prices or in block trades and subject to restrictions relating to volume, price and timing. The timing and extent of any purchases will depend upon market conditions, the trading price of the ADS's, the nature of other investment opportunities presented to NPD, NPD's cash flows and expected cash flows, general economic conditions and other factors. NPD may effect buyback transactions pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. NPD's board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size accordingly. NPD plans to fund repurchases made under this program from its available cash balance.

NPD operates retail drugstores in the People's Republic of China. As of December 31, 2008, NPD's store network comprised 2,709 directly operated stores located in 12 provinces and 76 municipalities in the People's Republic of China. NPD was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China.

To learn more about NPD visit:


China Pharma Holdings, Inc. (AMEX:CPHI)

CPHI, a leading fully-integrated specialty pharmaceuticals company in China, recently announced financial results for the second quarter ended June 30, 2010.

Second Quarter Highlights:

  • Revenue increased 22% to $16.6 million from $13.6 million in the second quarter of fiscal year 2009.
  • Gross profit grew 19% to $7.0 million from $5.9 million in the second quarter of fiscal year 2009.
  • Net income climbed 23% to $5.3 million, or $0.12 per basic and diluted share in the second quarter, from $4.3 million, or $0.10 per basic and diluted share a year ago.

CPHI, through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., manufactures, markets, and sells pharmaceuticals and nutritional supplements to hospitals and retailers. CPHI is based in Haikou, the People's Republic of China.

To learn more about CPHI visit:





Signup for FREE Daily Stock Alerts From 


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT)

Stocks: CPHI